

[illegible]

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC10664A	SERIAL NO. 09/451,641
			APPLICANT Danchen Gao, et al.	
			FILING DATE November 30, 1999	GROUP 1618
			Waterbeemd, et al., "Estimation of Solubility, Permeability, Absorption and Bioavailability", <i>Drug Bioavailability</i> , Vol. 8, pp. 207-209	
			Davies, et al., "Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib – A selective Cyclo-Coxygenase-2 Inhibitor", <i>Clin. Pharmacokinet</i> , Vol. 39(3); pp. 225-242 (2000)	
			Barnett International's Strategies for Improving Solubility, Practical Applications for Examining, Measuring, Predicting and Automating Solubility, June 2 – 4, 2004, Airport Marriott, Philadelphia, PA (6 pages)	
			2004 PSG Technical Conference, Current Pharmaceutical Products, What Was Once Novel is Now Standard, Le Jardin, 8440 Highway 27, Woodbridge, Ontario October 26 – 27, 2004 (8 pages)	
			Memet Bahar, Experimental Protocol – Crystallization Experiments, Product: Celecoxib; Preparation Date: 03.09-3.09.2004 (5 pages)	
			Davies, et al., "Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis", <i>Expert Opinion on Pharmacotherapy</i> , Vol. 2(1); pp. 139-152 (2001)	
			Declaration of Neal M. Davies dated November 17, 2004	
			Declaration of Dr. Tambay Taskin dated February 8, 2006	
			Kesten, "Control and Optimisation of Cement Quality with Laser Diffraction Particle Size Analysis and Dry Dispersion, Sympatec GmbH, D-38678 Clausthal-Zellerfeld, Germany (1997)	
			Clinical Trial Protocol N49-95-02-006, dated September 6, 1995	
			Internal redacted Pfizer document dated July 26, 2007 re: particle size analysis of Art X 200 mg tablets	
			Consultant Agreement re: Clinical Trial N49-95-02-006 dated September 20, 1995	
			Barber, et al., "A Logical Stepwise Approach to Laser Diffraction Particle Size Distribution Analysis Methods Development and Validation", <i>Pharmaceutical Development and Technology</i> , Vol. 3(2); pp. 153-161 (1998)	
			Pharmaceutical Dosage Forms: Tablets, 2 <sup>nd</sup> Edition, Vol. 2, (1990)	
			Jennings, et al., "Particle size measurement: the equivalent spherical diameter", <i>Proc. R. Soc. Lond. A</i> , Vol. 419, pp. 137-149 (1988)	
			United States Provisional Patent Application No. 60/047,535, filed May 22, 1997.	
			Affidavit of Professor Shimon Benita, filed in support of the Opposition of Teva Pharmaceuticals, Ltd. And Trima Israeli Medical Products Masbarot Ltd. in Israel (date unknown)	
			Affidavit of Professor Shimon Benita in response to Affidavits submitted by G.D. Searle & Co. by Professor Jurgensen, Dr. Davis and Mr. Goren, filed in Israeli opposition (date unknown)	
			Opposition by the Pharmaceutical Industry Chamber of Bolivia dated October, 2000 (English translation)	
			Rejection by Republic of Colombia dated March 16, 2005 (English translation)	
			Rejection by Costa Rica dated approx. 2008, later overcome. (English translation)	
			Affidavit of Dr. Cynthia Webb filed on behalf of Teva Pharmaceutical Industries Ltd. And Trima Israeli Medical Products Ltd. In Israeli opposition (date unknown)	
			Affidavit of Professor Avraham Danon, filed on behalf of Teva Pharmaceutical Industries Ltd. And Trima Israeli Medical Products Ltd. In Israeli opposition (date unknown)	
			Affidavit of Professor Avraham Danon in response to Affidavits submitted by G.D. Searle & Co. by Professor Jurgensen, Dr. Davis and Mr. Goren, filed in Israeli opposition (date unknown)	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC10664A	SERIAL NO. 09/451,641
			APPLICANT Danchen Gao, et al.	
			FILING DATE November 30, 1999	GROUP 1618
			Opposition filed by Association of Pharmaceutical Laboratories in Ecuador dated August, 2000 (English Translation)	
			Decision by European Patent Office in Appeal No. T0696/05-3302 dated February 5, 2009	
			Opposition decision by European Patent Office regarding European Patent No. EP1049467 dated March 30, 2005	
			Notice of Opposition by Teva Pharmaceutical Industries Ltd. and supporting documents dated July 8, 2003 regarding European Patent No. EP1049467	
			Opposition by Zentiva, k.s. in Estonia dated February 17, 2010 regarding Patent No. EE 04834	
			Opposition by Fako Ltd. in Eurasia regarding Eurasian Patent No. 3363 (English translation)	
			Affidavit of Neal M. Davies, Ph.D. dated March 2006, regarding Guatemalan Patent Application No. PI-990203 and US5,583,165	
			Final Decision filed in Guatemala ordering the Registry of Intellectual Property to proceed with respective registry regarding PI-1999-0203	
			Rejection filed regarding Application No. PI-990203 in Guatemala dated June 16, 2003	
			Administrative Appeal Brief regarding Application No. PI-990203 in response to the Guatemalan Examiner's rejection of June 16, 2003	
			Submission in Guatemala dated April, 2004	
			Israel opposition summations, July 2006 (English translation)	
			Opposition Decision by Israel Patent Office dated February 28, 2008 (English translation)	
			Appeal to Set Aside Refusal of Application and Reconsideration to Grant Patent to Philippine AN:1-1999-02951 dated July 28, 2009	
			Notice of Appeal by Teva Pharmaceutical Industries Ltd. and Trima Israeli Medical Products Maabarot Ltd., filed in Israel, dated June 5, 2009 (English translation)	
			Declaration by Neal M. Davies, Ph.D. dated November 10, 2004, filed in the Israel Opposition	
			Response to Statement filed by the Camara de la Industria Farmaceutica, in Venezuela regarding Venezuelan Patent Application No. 1999-002453	
			Annulment Action filed in Peru on January 11, 2010	
			Appeal filed by Polpharma in Poland regarding Polish Patent No. PL 200957 BI (English Translation)	
			Appeal filed by Zentiva in Poland regarding the granting of Patent No.PL 200957 (English Translation)	
			Decision of Industrial Property Office of the Slovak Republic dated April 26, 2010 regarding Slovak Republic Patent No. SK 283510 (English translation)	
			Nullity Action filed by Zentiva in Slovak Republic on July 19, 2008 (English translation)	
			Opposition arguments by Teva Pharmaceuticals in Israel (date unknown) (English translation)	
			Turkish opposition summary by Fako İlacları A.Ş. (June 18, 2001) (English translation)	
			Turkish opposition by Professor. Levent Öner dated June 5, 2001 (English translation)	
			Turkish opposition by TİM EKİP İLA, A.Ş. (2001) (English translation)	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.T./

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC10664A			SERIAL NO. 09/451,641		
			APPLICANT Danchen Gao, et al.					
			FILING DATE November 30, 1999			GROUP 1618		
			Turkish opposition by Nobel Ilac Sanayi Ve Ticaret, A.S. dated June 19, 2001 (English translation)					
			Turkish opposition statement by Fako Ilacлари dated June 18, 2001 (English translation)					
EXAMINER /Susan Tran/ DATE CONSIDERED /Susan Tran/								
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>								

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.T./